This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Financial goals should evolve with life. This guide covers indicators that warrant updating targets and practical steps to realign your plan.
22,496 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
A married pair earning $185,000 apiece can unlock about $94,000 in new Roth space in a single year by combining after...
A pivotal license extension in Ghana fuels a surge in Kosmos Energy. This article breaks down what the move means for...
As 2026 unfolds, social security changes still coming could affect your COLA, benefits, taxes, and how you reach the ...
A notable fund pulled out of a multi-million dollar DNOW position last quarter, triggering questions about strategy a...
Telos (TLS) 2026 earnings outlook is shaping up as multiple revenue streams converge—from on-chain activity fees to s...
A single market signal suggests SpaceX's IPO could roar, but history warns investors not to blindly chase headlines. ...
This summer's extreme weather could upend real estate plans and loan decisions. Learn which states face heightened cl...
Looking for nasdaq stocks before they soar in 2026? This article uncovers two compelling growth names, the catalysts ...
Regulatory clarity is on the horizon for digital assets as the Clarity Act advances. This guide breaks down three key...
Investors are watching Ambarella’s path to 2027 with a focus on growth drivers, margins, and the long-term AI camera ...
As Cognyte readies its Q1 2027 earnings report, investors want clarity on growth, margins, and cash flow. This guide ...